John Withington1, Joana B Neves1, Ravi Barod2. 1. Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, UK. 2. Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, UK. r.barod@nhs.net.
Abstract
PURPOSE OF REVIEW: This article aims to summarise recent developments in surgical and minimally invasive therapies in the management of small renal masses (SRMs). RECENT FINDINGS: The incidence of the small renal mass is increasing. Standard management of the SRM is partial nephrectomy. More recently, use of ablative techniques to manage the SRM has been increasing and an exciting array of technical advances is currently being made in the field. Nephron-sparing surgery looks set to become more financially viable with the advent of newer robotic platforms and, potentially, even less invasive with the evaluation of single-port access. Real-time imaging promises to improve tumour definition, nephron preservation and vascular management intraoperatively. Advances in surgical and minimally invasive therapies for the management of the SRM have the potential to improve cancer clearance and long-term renal function preservation. Patients will experience safer, more reliable and less invasive treatments for their small renal tumours. We describe the current advances underlying these changes.
PURPOSE OF REVIEW: This article aims to summarise recent developments in surgical and minimally invasive therapies in the management of small renal masses (SRMs). RECENT FINDINGS: The incidence of the small renal mass is increasing. Standard management of the SRM is partial nephrectomy. More recently, use of ablative techniques to manage the SRM has been increasing and an exciting array of technical advances is currently being made in the field. Nephron-sparing surgery looks set to become more financially viable with the advent of newer robotic platforms and, potentially, even less invasive with the evaluation of single-port access. Real-time imaging promises to improve tumour definition, nephron preservation and vascular management intraoperatively. Advances in surgical and minimally invasive therapies for the management of the SRM have the potential to improve cancer clearance and long-term renal function preservation. Patients will experience safer, more reliable and less invasive treatments for their small renal tumours. We describe the current advances underlying these changes.
Entities:
Keywords:
Ablation; Kidney cancer; Minimally invasive surgery; Small renal mass
Authors: R Houston Thompson; Brian R Lane; Christine M Lohse; Bradley C Leibovich; Amr Fergany; Igor Frank; Inderbir S Gill; Michael L Blute; Steven C Campbell Journal: Eur Urol Date: 2010-06-09 Impact factor: 20.096
Authors: Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2015-01-21 Impact factor: 20.096
Authors: Maxine Sun; Firas Abdollah; Marco Bianchi; Quoc-Dien Trinh; Claudio Jeldres; Rodolphe Thuret; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Ann Surg Oncol Date: 2012-02-10 Impact factor: 5.344
Authors: Mikhail Silk; David Tahour; Govindarajan Srimathveeravalli; Stephen B Solomon; Raymond H Thornton Journal: Semin Intervent Radiol Date: 2014-06 Impact factor: 1.513
Authors: Gladwin C Hui; Kemal Tuncali; Servet Tatli; Paul R Morrison; Stuart G Silverman Journal: J Vasc Interv Radiol Date: 2008-07-21 Impact factor: 3.464
Authors: Douglas Cheung; Jed Frankel; Pavinder Tut; Maria Komisarenko; Lisa Martin; Michael Jewett; Antonio Finelli Journal: Can Urol Assoc J Date: 2022-04 Impact factor: 2.052